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doi:10.1016/j.ejvs.2009.01.023Abstract Purpose: To evaluate the effectiveness of nitinol stent placement in long infrapo-
pliteal lesions in patients with critical limb ischaemia.
Materials and methods: Between January 2005 and January 2008, 34 high-risk patients (18
female; mean age: 73.8 6.1 years) with critical limb ischaemia underwent infragenicular
stenting. They had serious cardiovascular co-morbidities (>3, such as chronic obstructive
pulmonary disease (COPD), congestive heart failure and coronary artery occlusive disease),
American Society of Anaesthesiologists score of 3 or more, previous myocardial infarction,
coronary stent or bypass. The mean stenosis length was 6.5 0.9 cm (range: 2.2e8 cm), and
the mean occlusion length was 7.5 2.9 cm (range: 3e9.6 cm). Primary stent implantation
was performed for long stenosis or occlusion based on the TransAtlantic InterSociety Consensus
(TASC) C and D classification, secondary stenting for flow-limiting dissections or elastic recoil
after balloon dilatation. All patients who returned to the outpatient clinic were assessed for
claudication by clinical examination, ankleebrachial index (ABI) measurements, colour flow
and duplex Doppler ultrasound (US). Digital subtraction angiography was performed if resteno-
sis or re-occlusion was identified by Doppler US or transcutaneous measurement of partial
oxygen pressure (TcpO2) measurements, when appropriate.
Results: The technical success rate was 97.1% (33 of 34 cases). The crude rate of primary
patency rate was 91.1% during a follow-up period of 10.4 7.3 months. The mean anklee
brachial index increased significantly following intervention (0.45  0.25e0.92  0.13,
p< 0.001). Two patients underwent successful redo angioplasty after tibioperoneal interven-
tions due to in-stent restenosis (>70%) with relevant limitation of pain-free walking distance.
In another patient, bypass surgery to the anterior tibial artery 6 months after primaryK.P. Donas).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Below-knee Bare Nitinol Stent Placement in High-risk Patients 689intervention was necessary due to rest pain. Two patients required surgical revision of the
femoral artery after antegrade access. No procedure-related death was recorded in the entire
follow-up period.
Conclusions: The mid-term outcome underscores infrapopliteal stent placement as a reliable
treatment option in patients with critical limb ischaemia. In patients at high risk for crural
bypass, with no flow-limiting supragenicular lesions, below-knee stent-supported angioplasty
should be considered as a first choice of treatment.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Table 1 Patients’ demographic data
Rutherford category Patients
4 15/34 (44.1%)
5 19/34 (55.9%)
Age 73.8 6.1
Sex (male:female) 16:18
Factors of high-risk patients Patients
Arterial hypertension 18/34 (52.9%)
Cardiac insufficiency (NYHA >1) 8/34 (25%)
Pre-existing renal insufficiency 8/34 (25%)
Previous myocardial infarction,
coronary stent or bypass
6/34 (17.6%)
ASAZ 3 or more 22/34 (64.7%)
More than three risk factors 31/34 (91.2%)
ASA, American Society of Anaesthesiologists; NYHA, New York
Heart Association.Critical limb ischaemia manifests from advanced multi-
segmental atherosclerotic disease of the small- and
medium-sized vessels of the lower extremity. Surgical
bypass has been the first-line treatment of critical limb
ischaemia. However, many patients have poor distal target
vessels and absence of suitable veins to perform an autol-
ogous bypass. In addition, the associated mortality (6%) and
morbidity rates (wound infection: 30%, graft infection:
1.5%, myocardial ischaemia: 3% and graft stenosis or
occlusion: 15e30%) of the surgical approach for critical limb
ischaemia justifies re-evaluation of alternative treatment
modalities for this complex vascular problem.1
During the past decade, new developments in tech-
nology and technical skills have led to a continuous
improvement in the success rates of percutaneous trans-
luminal angioplasty (PTA) in the treatment of below-knee
lesions.2e4 The bypass vs. angioplasty in severe ischaemia
of the leg (BASIL) trial concluded that in patients with
chronic limb ischaemia due to infragenicular occlusive
atherosclerosis, lower limb bypass and balloon angioplasty
were associated with similar mid-term outcomes concern-
ing amputation-free survival.5 On the other hand, endo-
vascular approaches have several limitations.
Severe calcification, flow-limiting dissections and elastic
recoil are important factors linked to failure and compli-
cation rates of infrapopliteal PTA.6 Numerous reports7e12
have already attempted to evaluate the role of bare metal,
metal-absorbable, carbofilm-coated or drug-eluting stent
implantation in distal popliteal and infrapopliteal arteries.
However, the present status in the literature provides scant
information12e15 about the outcome of self-expanding bare
nitinol stents for below-knee lesions. This study aims to
assess the feasibility and effectiveness of the self-expand-
ing Xpert stent system (Abbott Vascular, Redwood City, CA,
USA) in the treatment of high-risk patients with critical limb
ischaemia.
Patients and Methods
Between January 2005 and January 2008, 34 high-risk
patients (18 female patients; mean age: 73.8 6.3 years)
who underwent primary or secondary infragenicular stent
placement of below-knee lesions, that is, popliteal (PIII
segment) and crural arteries, were retrospectively
reviewed. All patients suffered from critical limb ischaemia
based on the Rutherford categories. The baseline demo-
graphics of the patients are showed in Table 1. Of all the 34
patients, endovascular therapy was performed in 15
stenoses and in 19 occlusions. Themean stenosis length was6.5 0.9 cm (range: 2.2e8 cm), and the mean occlusion
length was 7.5 2.9 cm (range: 3e9.6 cm).
The therapy aimed to improve the run-off and to ensure
adequate patency in at least one below-knee vessel to the
ankle. The criteria for the stent implantation were long
stenosis or occlusion, classified based on the TransAtlantic
InterSociety Consensus (TASC) classification C lesions <3e
5 cm1 in three patients (mean length: 4.3 0.6 cm) and
TASC D lesions >5 cm1 in nine patients (mean length:
7.1 1.3 cm) or subsequent after PTA in case of (1) flow-
limiting dissections and/or (2) elastic recoil in the others
(64.8%).
The inflow of the popliteal artery was unlimited prior to
the below-knee intervention. In 25 patients (73.5%),
adequate inflow was obtained through PTA or stenting of
significant lesions of iliac (nZ 3), superficial femoral artery
(nZ 19) or both (nZ 3).
All patients were considered as high-risk patients,
defined by serious cardiovascular co-morbidities (>3, such
as chronic obstructive pulmonary disease (COPD), conges-
tive heart failure, coronary artery occlusive disease,
American Society of Anaesthesiologists score of 3 or more,
previous myocardial infarction, coronary stent or bypass).
No clopidogrel loading dose was used prior to intervention.
The post-interventional anti-platelet treatment included
administration of clopidogrel 75 mg daily for 6 weeks and
lifelong administration of acetylsalicylic acid 100 mg daily.
Critical limb ischaemia is defined as the presence of rest
pain, non-healing ulceration or gangrene and evidence of
690 K.P. Donas et al.diffuse pedal ischaemia (Fontaine classes III and IV or
Rutherford categories 4, 5 or 6: resting arterial pressure
(AP) <60 mmHg, ankle or metatarsal pulse volume
recording flat or barely pulsatile and toe pressure (TP)
<30 mmHg).
Follow-up
Peri- and post-interventional complications at the puncture
site were assessed in the first 24 h. All patients who returned
for routine follow-up control in the outpatient clinic were
evaluated for claudication by clinical examination, anklee
brachial index (ABI) measurements, colour flow and duplex
Doppler ultrasound (US) before hospital discharge at 3, 6 and
12 months later and yearly thereafter. Digital subtraction
angiography was performed if restenosis or re-occlusion was
identified by duplex Doppler US. The mean follow-up period
was 10.4 7.3 months. Our institution does not require
ethical approval for reports such as this.
Definitions
Anatomical patency was defined as the absence of recur-
rent occlusion or stenosis of the treated segment more than
50% in diameter, documented by colour flow and duplex
Doppler US or digital subtraction angiography. Technical
success was determined as being less than 30% of the final
residual stenosis measured at the narrowest point of the
treated vascular segment. To document haemodynamic
success, resting ABI measurements at baseline, at 12e24 h
after endovascular treatment and at most recent follow-up
were performed. On a short-term and long-term basis, the
ABI-based definition of success was indicated by an increase
of at least 0.10 relative to baseline measurement.
The measurement of ABI in the crural arteries in six
patients with diabetes mellitus was not reliable due to
medial sclerosis of the Mo¨nckeberg type. They had an ABI
index >1.5 of the lower limbs. To noninvasively assess the
influence of stent placement in the peripheral circulation
of these patients, we used transcutaneous measurement of
partial oxygen pressure (TcpO2) at the dorsal site of the
foot. The TcpO2 electrodes (the Clark-type oxygen-sensing
electrodes) were attached to the skin, and the heating
element of the electrode was warmed to 45 C. One elec-
trode was attached to the dorsum of the foot and the other
to the chest. The TcpO2 measurements were performed,
with the patient resting in the supine position, using the
Hellige O2 monitor.
Clinical success was defined by sustained clinical
improvement, as categorised by Rutherford guidelines, and
included haemodynamic and clinical measures.
Complications of treatment were classified on the basis
of outcome according to the reporting standards of the
Society of Interventional Radiology.12 An ethical approval
for the present retrospective study was not necessary at
our institution.
Intervention
The contralateral common femoral approach with the use
of 5F sheath and 0.035 Terumo guidewire was preferablyused. The indications for ipsilateral puncture of the
common femoral artery were previous vascular recon-
struction by synthetic patch or bypass and morphology of
the iliac artery unsuitable for cross-over manoeuvre, that
is, steep aortic bifurcation, tortuous or calcified iliac
arteries, or failure to cross the lesions from the contralat-
eral side due to poor pushability. An angiography of the
infrarenal abdominal aorta, iliac and peripheral segments
was performed as well. In order to catheterise the
contralateral ilio-femoral segment with ipsilateral crural
lesions using the cross-over technique, the 5F sheath was
changed to 6F long sheaths (90 cm). Intra-operative
administration of 5000 IU heparin was routinely made.
For PTA, low-profile balloon catheters (Submarine and
Amphirion; Invatec, Roncadelle, Italy) with diameters
ranging from 2 to 4 mm and lengths ranging from 20 to
80 mm were used based on the size of the relevant artery.
The balloon pressure ranged from 6 to 16 atm, and balloon
inflation was performed routinely at the stented lesion. The
criteria for the stent implantation after PTA were (1) TASC
C lesions <3e5 cm and TASC D lesions >5 cm, (2) flow-
limiting dissections and/or (3) elastic recoil.
The Xpert stent system (Abbott Vascular, Redwood City,
CA, USA) is a self-expanding nitinol stent, specifically
designed for infragenual lesions of small vessels. The device
is compatible with a 4F sheath and has a diameter of 3e
8 mm and a length of 20e60 mm. Recently, the stent is also
available in a length of 120 mm. Fig. 1aec show intra-
operative angiography of the right infrapopliteal arteries
after the successful Xpert stent system implantation in
popliteal segment (III) and fibular artery.
In one patient, the implantation of the Xpert stent
system was not possible due to friction caused by extensive
atherosclerosis of the anterior tibial artery, and, therefore,
the Chromis Deep stent (Invatec, Roncadelle, Italy) was
used. The Chromis Deep stent is cobaltechromium balloon-
expandable stent with a closed cell design.
Statistical analysis
Descriptive data are presented as mean standard devia-
tion (SD) and range, if appropriate; nominal data are given
as counts and percentages; continuous quantitative data
were compared with the non-parametric, two-sample,
Wilcoxon signed-rank test. Statistical significance was set
at a p-value of less than 0.05. The primary patency rate was
calculated by crude rates.
Results
The technical success rate was 97.1% (33 of 34 cases). In
one patient, the implantation of the Xpert stent system was
not possible due to friction caused by extensive athero-
sclerosis of the tibial artery, and, therefore, the Chromis
Deep stent was successfully implanted.
Contralateral access was performed in 26 cases (76.4%).
An ipsilateral access was preferred in eight patients. Four
patients had had a previous vascular reconstruction of the
contralateral side by synthetic patch, two patients had
unsuitable morphology of the iliac bifurcation and the other
two had failed endovascular re-canalisation of the lesions
Table 2 Overview of the results
Patients with critical limb
ischaemia who underwent
below-knee bare-stent
placement
34
Primary patency 93.75%
Re-interventions
Balloon angioplasty 2/34 (5.8%)
Bypass surgery 1/34 (2.9%)
Major adverse event 0/34 (0%)
Access-site complications 2/34 (5.8%)
Bypass surgery: extra-anatomic tibial anterior bypass (Stock-
mann bypass); Major adverse events including deaths and major
amputations; Access-site complications: haematoma/bleeding
with surgical repair.
Figure 1 (a and b) Angiographic view of the long high-grade stenosis of the popliteal artery in the 3rd segment and tibiofibular
tractus with concomitant high-grade stenosis of the proximal anterior tibial artery. Intra-operative angiography of the right
infrapopliteal arteries after the Xpert stent system implantation in popliteal segment (III) and fibular artery and PTA of the
proximal anterior tibial artery. (c) Primary infrapopliteal application of the Xpert stent system (4 80 mm) in a patient with critical
limb ischaemia in the deep popliteal and fibular artery with TASC D lesion.
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number of applied stents was 38 (mean: 1.1 0.3 per
patient; range: 1e2 per patient): 29 stents were deployed
in the crural axis and nine stents in the distal popliteal
artery. In 32 out of 34 patients (94.1%), a single stent was
implanted. In two patients (5.9%), a stent-overlapping was
necessary due to extensive flow-limiting dissection.
No early (<30-day) morbidity and mortality was noted,
and the primary cumulative patency was 100%. The primary
cumulative patency rate at 10.4 7.3 months was 93.75%.
Two patients underwent successful redo angioplasty due to
in-stent restenosis (>70%) in the tibioperoneal trunk and due
to relevant limitation of pain-freewalking distance at 6 and 8
months after the primary procedure. No evidence of stent
fracture was noted in these cases. One patient presented
with rest pain with angiographic evidence of inadequate
inflow to the occluded segment and, therefore was treated
by extra-anatomic bypass to the anterior tibial artery.
The 6-month amputation-free interval for the patients
who suffered from critical limb ischaemia was 100%, with
a 100% limb-salvage rate. All patients showed improvement
of their symptoms, that is, healing of the ulceration for the
patients with trophic lesions. The ABI index increased at
12e24 h significantly (pre-intervention: 0.45 0.25; post-
intervention: 0.92 0.13, p< 0.001). A sustained
improvement of the ABI index has been shown at 6 months
post-interventionally (0.77 0.23, p< 0.001). The six
patients with diabetes mellitus and not reliable ABI
measurements showed an increase in baseline TcpO2 values
of the limb with the leading symptom from 9.3 3.3 to
23.3 2.3 mmHg (p> 0.5).The overall complication rate was 5.8% (2 of 34). Two
patients suffered from false aneurysms at the puncture site
in the groin after antegrade access and use of 6F sheath. A
surgical evacuation of the haematoma and revision of the
common femoral access was necessary. No patient died due
to procedure-related cause during either the procedure or
the follow-up period. Moreover, no evidence of cardio-
respiratory complication, such as myocardial infarction or
decompensate respiratory insufficiency or impairment of
the renal function, was noted in our patient group. Table 2
summarises the results of our study.
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Patients with critical limb ischaemia normally present with
long diffuse segments of stenotic and/or occlusive disease,
in densely calcified vessels, with compromised in-flow and
poor run-off. Moreover, these patients are typically elderly
with severe co-morbidities, making the surgical bypass
prohibitive in these cases. Therefore, successful re-vascu-
larisation of these complex lesions remains challenging and
increases the interest in further development of endovas-
cular strategies in this clinical entity.
To our knowledge, the present study reports one of the
largest series of stent implantation in the crural arteries in
patients with critical limb ischaemia. In comparison with
the report of Bern,14 we found a high technical success rate
(97.1%) and a limb-salvage rate of 100%.
Only two (5.8%) of our patients required a stent overlap,
due to unavailability of stents of 80 mm or 120 mm length
at that time. Generally, stent-overlapping minimises the
vessel lumen and increases flow disturbances with consec-
utive neo-intimal hyperplasia, which is linked to restenosis
or re-occlusion. Moreover, according to Duda et al.,15 the
above-mentioned phenomenon may be an underlying
mechanism for the occurrence of stent fractures.
The positive impact of nitinol stents in femoro-popliteal
arteries, in terms of significantly improving of patency rates,
compared with stainless steel stents or balloon angioplasty
with optional stenting has already been described.12,13,16 At
themoment, the literature provides scant information about
the feasibility and effectiveness of bare nitinol stent
placement in below-the-knee lesions. Kickuth et al.14 per-
formed a 4F-sheath-compatible, self-expanding nitinol
stent-supported angioplasty by the Xpert system in distal
popliteal and crural arteries and found a marked clinical
improvement of 80%. The trial showed an excellent push-
ability and trackability of the stent, which is specifically
designed for small vessels with a low strut profile.
The flexibility of the device is beneficial, especially for
the infragenicular lesions of the third popliteal segment and
proximal part of the crural arteries. This technical point
contributes to optimising the vessel lumen and minimising
the flow disturbances, even in tortuous anatomy. The length
of the device up to 120 mm allows the treatment of long
lesions, which are very common in the crural arteries.
Limitations of theXpert stent systemare the poor visibility,
especially in cases of severe calcification of the vessel lumen.
Therefore, in one case with focal tortuous calcification and
high friction in the middle segment of the tibial artery, we
used a balloon-expandable stent. Moreover, below-knee stent
placement is only possible in cases of unlimited supragenicular
inflow. This condition is rarely present due to the multi-
segmental nature of the disease and requires simultaneous
treatment of the more proximal lesions which can often be
hazardous, especially in case of TASC D lesions.
Siablis et al.17 compared sirolimus-eluting stents to
bare-metal stents in infrapopliteal lesions in the critical
limb ischaemia population. The outcomes of this non-
randomised prospective study showed a significant
improvement of 6-month patency rate (92% vs. 68%,
pZ 0.002) for the patients group treated by sirolimus-
eluting stent in short lesions using 20-mm stents. On theother hand, majority of the infrapopliteal lesions are long
and, therefore, any attempt to draw conclusion about
superiority of one type of the stents is questionable.
Limitation of the present study is the fact that it is
retrospective, non-randomised data analysis, with a small
number of patients without a control group. Although this
series reflects feasibility, any comparison with crural PTA or
bypass seems premature at the present moment. However,
in case of high-risk patients with critical peripheral arterial
disease and unlimited supragenicular inflow, below-knee
stent-supported angioplasty should be considered as
a bailout procedure of first choice.
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